TRDA Stock Summary and Trading Ideas (Entrada Therapeutics | NASDAQ:TRDA)

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Entrada Therapeutics trades on the NASDAQ stock market under the symbol TRDA.

As of January 3, 2025, TRDA stock price climbed to $18.31 with 115,757 million shares trading.

TRDA has a beta of 2.54, meaning it tends to be more sensitive to market movements. TRDA has a correlation of 0.32 to the broad based SPY ETF.

TRDA has a market cap of $684.90 million. This is considered a Small Cap stock.

Last quarter Entrada Therapeutics reported $20 million in Revenue and -$.35 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.38.

In the last 3 years, TRDA traded as high as $24.38 and as low as $5.12.

The top ETF exchange traded funds that TRDA belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

TRDA has outperformed the market in the last year with a price return of +32.7% while the SPY ETF gained +27.8%. TRDA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +11.4% and +4.1%, respectively, while the SPY returned +4.6% and +0.1%, respectively.

TRDA support price is $16.75 and resistance is $18.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TRDA shares will trade within this expected range on the day.